Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV

Sengül Üçer; Pınar Gürkaynak; Uğur Emre Gümüş; Melek Sena Altun; Şerife Altun Demircan; Esra Kaya Kılıç; Cigdem Ataman Hatipoglu; Gunay Tuncer Ertem; Salih Cesur; Sami Kınıklı

doi:10.18678/dtfd.1910893

Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV

Abstract

Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathways. HIV/HBV coinfection is associated with accelerated liver disease progression. Consequently, hepatitis B vaccination is a critical preventive measure for PLWH. This study was designed to assess the serological response to hepatitis B vaccination in PLWH.

Material and Methods: PLWH followed at the Infectious Diseases and Clinical Microbiology Clinic who were seronegative for HBsAg, anti-HBs, and anti-HBc IgG were retrospectively identified. Anti-HBs levels measured 1 month to 1 year after the final vaccine dose were assessed. Criteria associated with low response (anti-HBs titer: <100 mIU/mL) and high response (≥100 mIU/mL) were also evaluated.

Results: A total of 54 patients were included in the final analysis. The median age was 43 (range, 22–80) years and 25.9% of the patients were female. Forty-nine patients (90.7%) had anti-HBs levels ≥10 mIU/mL. Anti-HBs levels ≥100 mIU/mL were observed in 10 (28.6%) patients who had received at least one double-dose vaccination versus 3 (15.8%) patients who had not (p=0.341), and in 18 (51.4%) patients with undetectable HIV RNA versus 5 (26.3%) patients with detectable HIV RNA (p=0.091), without reaching statistical significance.

Conclusion: Adherence to the hepatitis B vaccination schedule was found to be suboptimal. Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.

Keywords

Ethical Statement

The study was approved by the Ethics Committee of the Ankara Training and Research Hospital (E-24-292,07.11.2024).

References

Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27(3):294-315. doi:10.1111/jvh.13217.
Peng A, Wang L, Waleed K, Qiu L, Tong X, Tu Z, et al. The prognosis characteristics of HIV/HBV co-infection after antiviral therapy: a comprehensive review. Infect Agent Cancer. 2026;21(1):15. doi:10.1186/s13027-025-00724-5.
Xu M, Warner C, Duan X, Cheng Z, Jeyarajan AJ, Li W, et al. HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway. J Hepatol. 2024;80(6):868-81. doi:10.1016/j.jhep.2024.01.026.
Kolakowska A, Marshall E, Krastinova E, Cros A, Duvivier C, Leroy P, et al. Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region. Vaccine. 2024;42(17):3655-63. doi:10.1016/j.vaccine.2024.04.077.
Garcia A, Vigil KJ, Taylor B, Kshirsagar O, Thamer M, Jain MK. Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change? J Viral Hepat. 2023;30(10):790-2. doi:10.1111/jvh.13868.
Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, et al. Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. HIV Med. 2026;27(1):18-32. doi:10.1111/hiv.70120.
Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune response to Hepatitis B virus vaccine among people living with HIV: a meta-analysis. Front Immunol. 2021;12:745541. doi:10.3389/fimmu.2021.745541.
Corcorran MA, Kim HN. Strategies for Hepatitis B virus prevention in people living with HIV. Curr HIV/AIDS Rep. 2023;20(6):451-7. doi:10.1007/s11904-023-00670-0.

Ursenbach A, Séverac F, Chahard A, Alfaiate D, Bani-Sadr F, Hocqueloux L, et al. Hepatitis B surface antibody clearance after vaccination in people with HIV. Open Forum Infect Dis. 2025;13(1):ofaf754. doi:10.1093/ofid/ofaf754.
Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040-4. doi:10.1016/j.vaccine.2012.12.047.
Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30(41):5973-7. doi:10.1016/j.vaccine.2012.07.028.
Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409. doi:10.1371/journal.pone.0080409.
Tengan FM, Abdala E, Nascimento M, Bernardo WM, Barone AA. Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):587. doi:10.1186/s12879-017-2695-z.
Togan RM, Youa FI, Atoun RC, Bigma M, Konu RY, Sadio AJ, et al. Viral hepatitis B co-infection among people living with HIV: a national cross-sectional survey in Togo in 2023. BMC Infect Dis. 2025;25(1):1432. doi:10.1186/s12879-025-11822-5.
Steedman NM, McMillan A. Hepatitis B testing and vaccination in patients recently diagnosed with HIV infection. Int J STD AIDS. 2008;19(2):83-4. doi:10.1258/ijsa.2007.007144.
Sheikh D, Staggers KA, Carey J, Keitel WA, Atmar RL, El Sahly HM, et al. Delays in Hepatitis B immunization series completion in people with human immunodeficiency virus. Open Forum Infect Dis. 2023;10(11):ofad543. doi:10.1093/ofid/ofad543.
Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38(10):1478-84. doi:10.1086/420740.
Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccin Immunother. 2017;13(6):1-10. doi:10.1080/21645515.2016.1277844.
Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12(12):966-76. doi:10.1016/S1473-3099(12)70243-8.
Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther. 2006;3:9. doi:10.1186/1742-6405-3-9.
Khaimova R, Fischetti B, Cope R, Berkowitz L, Bakshi A. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. Vaccine. 2021;39(44):6529-34. doi:10.1016/j.vaccine.2021.09.050.
Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283-91. doi:10.1016/S1473-3099(15)00220-0.
Vargas JI, Jensen D, Martínez F, Sarmiento V, Peirano F, Acuña P, et al. Comparative efficacy of a high-dose vs standard-dose Hepatitis B revaccination schedule among patients with HIV: a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2120929. doi:10.1001/jamanetworkopen.2021.20929.
Lee JH, Hong S, Im JH, Lee JS, Baek JH, Kwon HY. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. Vaccine. 2020;38(24):3995-4000. doi:10.1016/j.vaccine.2020.04.022.
Nie L, Hua W, Liu X, Pang X, Guo C, Zhang W, et al. Associated Factors and Immune Response to the Hepatitis B Vaccine with a Standard Schedule: A Prospective Study of People with HIV in China. Vaccines (Basel). 2023;11(5):921. doi:10.3390/vaccines11050921.
Joshi SS, Davis RP, Ma MM, Tam E, Cooper CL, Ramji A, et al. Reduced immune responses to Hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines. 2021;6(1):9. doi:10.1038/s41541-020-00266-4.

Details

Primary Language

English

Subjects

Infectious Diseases

Journal Section

Research Article

Authors

Sengül Üçer ^*
0000-0002-1764-3198
Türkiye

Pınar Gürkaynak
0000-0001-8863-8268
Türkiye

Uğur Emre Gümüş
0009-0009-4681-9568
Türkiye

Melek Sena Altun
0000-0002-5612-7305
Türkiye

Şerife Altun Demircan
0000-0002-9295-4578
Türkiye

Esra Kaya Kılıç
0000-0002-3270-4841
Türkiye

Cigdem Ataman Hatipoglu
0000-0002-1104-8232
Türkiye

Gunay Tuncer Ertem
0000-0001-8760-0030
Türkiye

Salih Cesur
0000-0003-4960-7375
Türkiye

Sami Kınıklı
0000-0002-9661-7851
Türkiye

Publication Date

August 21, 2026

Submission Date

March 16, 2026

Acceptance Date

August 16, 2026

Published in Issue

Year 2026 Volume: 28 Number: 2

DOI

https://doi.org/10.18678/dtfd.1910893

IZ

https://izlik.org/JA77AJ65YF

Cite

RIS / Bibtex

APA

Üçer, S., Gürkaynak, P., Gümüş, U. E., Altun, M. S., Demircan, Ş. A., Kaya Kılıç, E., Ataman Hatipoglu, C., Tuncer Ertem, G., Cesur, S., & Kınıklı, S. (2026). Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Duzce Medical Journal, 28(2), 207-211. https://doi.org/10.18678/dtfd.1910893

AMA

1.Üçer S, Gürkaynak P, Gümüş UE, et al. Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Duzce Med J. 2026;28(2):207-211. doi:10.18678/dtfd.1910893

Chicago

Üçer, Sengül, Pınar Gürkaynak, Uğur Emre Gümüş, et al. 2026. “Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living With HIV”. Duzce Medical Journal 28 (2): 207-11. https://doi.org/10.18678/dtfd.1910893.

EndNote

Üçer S, Gürkaynak P, Gümüş UE, Altun MS, Demircan ŞA, Kaya Kılıç E, Ataman Hatipoglu C, Tuncer Ertem G, Cesur S, Kınıklı S (August 1, 2026) Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Duzce Medical Journal 28 2 207–211.

IEEE

[1]S. Üçer et al., “Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV”, Duzce Med J, vol. 28, no. 2, pp. 207–211, Aug. 2026, doi: 10.18678/dtfd.1910893.

ISNAD

Üçer, Sengül - Gürkaynak, Pınar - Gümüş, Uğur Emre - Altun, Melek Sena - Demircan, Şerife Altun - Kaya Kılıç, Esra - Ataman Hatipoglu, Cigdem - Tuncer Ertem, Gunay - Cesur, Salih - Kınıklı, Sami. “Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living With HIV”. Duzce Medical Journal 28/2 (August 1, 2026): 207-211. https://doi.org/10.18678/dtfd.1910893.

JAMA

1.Üçer S, Gürkaynak P, Gümüş UE, Altun MS, Demircan ŞA, Kaya Kılıç E, Ataman Hatipoglu C, Tuncer Ertem G, Cesur S, Kınıklı S. Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Duzce Med J. 2026;28:207–211.

MLA

Üçer, Sengül, et al. “Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living With HIV”. Duzce Medical Journal, vol. 28, no. 2, Aug. 2026, pp. 207-11, doi:10.18678/dtfd.1910893.

Vancouver

1.Sengül Üçer, Pınar Gürkaynak, Uğur Emre Gümüş, Melek Sena Altun, Şerife Altun Demircan, Esra Kaya Kılıç, Cigdem Ataman Hatipoglu, Gunay Tuncer Ertem, Salih Cesur, Sami Kınıklı. Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Duzce Med J. 2026 Aug. 1;28(2):207-11. doi:10.18678/dtfd.1910893